Small molecule disruption of the LAG-3/HLA-II interaction: implications for modulating T-cell responses

Mason, Georgina 2019. Small molecule disruption of the LAG-3/HLA-II interaction: implications for modulating T-cell responses. PhD Thesis, Cardiff University. Item availability restricted.

Preview	PDF - Accepted Post-Print Version Download (6MB) | Preview
	PDF (Cardiff University Electronic Publication Form) - Supplemental Material Restricted to Repository staff only Download (105kB)

Abstract

Background Although recent advances in immunotherapy have given some remarkable results in patients with advanced cancers, they are only effective in a proportion of patients, and the search for more effective novel treatments is keenly pursued. Co-inhibitory receptor lymphocyte activation gene-3 (LAG-3) has been shown to inhibit immune responses and therefore, is an attractive target. Despite the importance of LAG-3 in multiple disease settings, including cancer, the role of LAG-3 is yet to be fully understood. However, it is possible that use of a LAG-3 inhibitor, in combination with other cancer therapies, will enhance the anti-tumour immune response. In this study, a novel screening strategy was developed and used to screen a small molecule library against LAG-3 binding to key ligand major histocompatibility complex (MHC)-II. Results AlphaScreen was developed as a screening strategy for weak protein/protein interactions (PPI). Initially the assay was developed using a model low affinity PPI: the T-cell receptor (TCR) binding to peptide-MHC targets. Having demonstrated the effectiveness of AlphaScreen for detecting very low affinity PPI, this approach was subsequently used to explore the biology of LAG-3/MHC-II interactions using a range of HLA (human leukocyte antigen)-DR and –DQ molecules. Following on from this, a high through-put small molecule library screen was employed to selectively inhibit LAG3 binding to HLA-II. From a library of 50 000 small molecules, 8 hit compounds were found. These compounds were tested in a cell toxicity assay, 6 of which were found to be nontoxic. Finally, to develop the whole cell assays further, substantial progress towards development of a LAG-3 reporter cell line was made, using a LAG-3-CD3ζ chimeric receptor in a NFAT reporter cell line. Conclusions The AlphaScreen assay was highly effective at interrogating low affinity PPI. This enabled LAG-3 binding to a range of HLA-II molecules to be examined and allowed identification of specific inhibitors of this interaction. These small molecules will be examined in the future to develop clinically relevant inhibitors.

Item Type:	Thesis (PhD)
Date Type:	Completion
Status:	Unpublished
Schools:	Medicine
Date of First Compliant Deposit:	20 December 2019
Last Modified:	19 Jul 2024 01:30
URI:	https://orca.cardiff.ac.uk/id/eprint/127662

Actions (repository staff only)

Edit Item